Market Cap
$1.6B
TSHA
Taysha Gene Therapies, Inc.
$4.63 ▼ -2.32%
Prev close $4.74Market cap$1.6B
ConsensusStrong Buy
12-mo target$13.00 (+180.8%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)30 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TSHA right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$1.5B
Inst. Activity
30 buys / 10 sells
Insider Activity
$0.00 buy / $2.1M sell
Insider Net $
-$2.1M
SEC Reports
8
Press Releases
4
Price chart 30d -16.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Aug 11, 2026 SEC Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the
Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus of -$0.11 by 18.2%, with zero revenue vs. $1.99M
PRESS-RELEASE — Impact 5/10
Jul 10, 2026 Insider
Nagendran Sukumar sold 200,000 shares
President and Head of R&D @ $6.24 ($1.2M)
Jun 30, 2026 Inst.
WELLINGTON MANAGEMENT GROUP LLP — DOUBLED
3,975,605 shares ($27.1M)
Jun 30, 2026 Inst.
Jun 26, 2026 SEC HEALTHCARE OF ONTARIO PENSION — ADD
3,885,501 shares ($26.5M)
Taysha Gene Therapies is raising approximately $187.4 million ($215.6 million if underwriters' option is exercised) thro
424B5 — Impact 6/10
Taysha Gene Therapies priced a $200M underwritten public offering of 32,500,001 common shares at $6.00/share and 833,333
8-K — Impact 5/10
Taysha Gene Therapies announced the pricing of a $200M underwritten public offering of 32.5M shares at $6.00/share, plus
Impact 7/10
Analyst ratings buy % -1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 17, 2026 | Wolfe Research | INITIATE | Outperform | 52% |
| Jul 21, 2026 | Goldman Sachs | MAINTAIN | Buy | 54% |
| Jul 2, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| Jun 30, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jun 30, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Jun 23, 2026 | BMO Capital | MAINTAIN | Outperform | 53% |
| Jun 23, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| Jun 23, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Jun 22, 2026 | Needham | MAINTAIN | Buy | 50% |
| Apr 6, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 6 | 12 | 1 | 0 | 0 | 95% | |
| Jun 1, 2026 | 6 | 12 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% |
Price targets
Where 13 covering analysts think TSHA trades over the next 12 months.
$13.00 +180.8% upside Strong Buy
Current$4.63 Low$9.00 Median$12.00 High$19.00 13 analysts
$9.00$19.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 0 bullish, 1 bearish, 2 mixed, 5 neutral · avg impact 4.4/10.Plus 4 press releases.
NEUTRALPRESS-RELEASE5/10
Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus of -$0.11 by 18.2%, with zer
Aug 11, 2026
BEARISH424B56/10
Taysha Gene Therapies is raising approximately $187.4 million ($215.6 million if underwriters' optio
Jun 26, 2026
MIXED8-K5/10
Taysha Gene Therapies priced a $200M underwritten public offering of 32,500,001 common shares at $6.
Jun 26, 2026
NEUTRAL8-K5/10
Taysha Gene Therapies reported Q1 2026 financial results with a net loss of $42.4M ($0.12/share), wi
May 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company f
Oct 1, 2026
short_volume
Short Volume: TSHA — 69.2% short (0.5M / 0.8M)
Short: 538,550 | Exempt: 172 | TRF Vol: 778,127 | Short Ratio: 69.2% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: TSHA — 83.5% short (0.9M / 1.0M)
Short: 865,350 | Exempt: 75 | TRF Vol: 1,035,773 | Short Ratio: 83.5% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: TSHA — 83.1% short (1.0M / 1.3M)
Short: 1,049,032 | Exempt: 230 | TRF Vol: 1,262,662 | Short Ratio: 83.1% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: TSHA — 67.8% short (0.9M / 1.3M)
Short: 852,627 | Exempt: 65 | TRF Vol: 1,257,142 | Short Ratio: 67.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.13 | $-0.14–$-0.10 | -42.9% | -4.2% | 0↑ 3↓ | $0.0B | 4 |
| Next Q | $-0.13 | $-0.15–$-0.11 | -81.1% | -15.2% | 0↑ 3↓ | $0.0B | 4 |
| Current FY | $-0.47 | $-0.58–$-0.38 | -49.1% | -7.7% | 0↑ 3↓ | $0.0B | 5 |
| Next FY | $-0.46 | $-0.53–$-0.43 | 2.4% | -6.3% | 0↑ 3↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.125 | — |
| 7d ago | $-0.125 | — |
| 30d ago | $-0.120 | -0.005 |
| 60d ago | $-0.120 | -0.005 |
| 90d ago | $-0.122 | -0.003 |
Institutional ownership
Which big funds own TSHA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.5B total value (223,080,887 shares) as of 2026-Q2. Top holders: Avoro, RA, GOLDMAN. Net buying activity: 30 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 23,888,888 | $162.7M | 10.7% | — |
| RA CAPITAL MANAGEMENT, L.P. | 23,555,648 | $160.4M | 10.6% | — |
| GOLDMAN SACHS GROUP INC | 22,713,118 | $154.7M | 10.2% | — |
| BlackRock, Inc. | 20,691,927 | $140.9M | 9.3% | — |
| MORGAN STANLEY | 16,487,479 | $112.3M | 7.4% | — |
| RTW INVESTMENTS, LP | 13,560,258 | $92.3M | 6.1% | — |
| FMR LLC | 13,336,413 | $90.8M | 6.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 12,478,595 | $85.0M | 5.6% | — |
| STATE STREET CORP | 11,421,920 | $77.8M | 5.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 6,560,394 | $44.7M | 2.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 626,361 | 3,975,605 | +534.7% | $27.1M |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | ADD | 2,883,301 | 3,885,501 | +34.8% | $26.5M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 2,022,498 | 3,140,009 | +55.3% | $21.4M |
| Pictet Asset Management Holding SA | DOUBLED | 19,318 | 2,770,701 | +14242.6% | $18.9M |
| Aberdeen Group plc | DOUBLED | 1,021,063 | 2,327,152 | +127.9% | $15.8M |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | NEW | — | 2,250,000 | — | $15.3M |
| NORGES BANK | NEW | — | 2,233,600 | — | $15.2M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 3,281,820 | 2,126,838 | -35.2% | $14.5M |
| BARCLAYS PLC | TRIM | 2,812,010 | 1,630,659 | -42.0% | $11.1M |
| CITADEL ADVISORS LLC | DOUBLED | 411,135 | 1,535,287 | +273.4% | $10.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 12 transactions. Net -$2.1M — $0.00 bought, $2.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 10, 2026 | Nagendran Sukumar | President and Head of R&D | SELL | 200,000 | $6.24 | $1.2M |
| Jun 1, 2026 | Long Alison S | Director | AWARD | 21,335 | — | — |
| Jun 1, 2026 | Stalfort John A III | Director | AWARD | 21,335 | — | — |
| Jun 1, 2026 | Long Alison S | Director | AWARD | 42,671 | — | — |
| Jun 1, 2026 | Donenberg Phillip B. | Director | AWARD | 21,335 | — | — |
| Jun 1, 2026 | Donenberg Phillip B. | Director | AWARD | 42,671 | — | — |
| Jun 1, 2026 | Sepp-Lorenzino Laura | Director | AWARD | 42,671 | — | — |
| Jun 1, 2026 | Stalfort John A III | Director | AWARD | 42,671 | — | — |
| Jun 1, 2026 | Sepp-Lorenzino Laura | Director | AWARD | 21,335 | — | — |
| Apr 10, 2026 | Nagendran Sukumar | President and Head of R&D | EXERCISE | 19,021 | $1.71 | $32.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TSHA.
Shares short
51,405,384
Settlement Sep 15, 2026
Change vs prior
+9.8%
Semi-monthly cycle
Days to cover
18.8
At avg daily volume
Of shares outstanding
≈15.8%
Estimate — not % of float
All TSHA filing & press-release reports (12)
- PRESS-RELEASE reportAug 11, 2026
- 424B5 reportJun 26, 2026
- 8-K reportJun 26, 2026
- PRESS-RELEASE reportJun 25, 2026
- PRESS-RELEASE reportJun 5, 2026
- 8-K reportMay 6, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportApr 27, 2026
- DEFA14A reportApr 22, 2026
- 144 reportApr 10, 2026
- PRESS-RELEASE reportMar 19, 2026